The Control Cases: How Other Conditions Escaped
SLE: The Immunology Fortress
SLE (9:1 female) successfully migrated into high-reimbursement "immunology" rather than "women's health." How: granular ICD-10 codes (M32.11-14) allow upcoding by organ involvement. Protected-class status under Medicare Part D ensures formulary access. SLE was framed as "organ preservation" - preventing kidney/cardiac damage. Women's health conditions are framed as "quality of life." This framing is systematically devalued by every HTA system.
MASH: From "Lifestyle" to "Fibrosis"
For decades, fatty liver was treated like obesity: a "lifestyle" condition. The field shifted by redefining the endpoint from symptoms to organ damage (fibrosis). By anchoring to histological evidence, MASH aligned with "organ preservation." The first FDA-approved treatment (Rezdiffra) requires confirmed fibrosis via biopsy. This biomarker anchoring is exactly what women's health lacks.
Why Women's Health Remains Trapped
PCOS: The Coding Void
Up to 15% prevalence, $8B annual US cost. But a PCOS patient sees dermatology (skin code), gynecology (OC prescription), endocrinology (pre-diabetes code). The PCOS diagnosis never aggregates in payer data. NIH funding: ~$215M over a decade vs. $609M for SLE.
Endometriosis: The One-Code Problem
CPT 58662 covers everything from 20-minute ablation to 4-hour deep excision. No complexity modifiers. Compare: hernia codes stratify by size, reducibility, and incarceration. A surgeon performing 4-hour excision could otherwise perform 3 hysterectomies or 4 hernias at double the revenue - driving prevalence of ineffective ablation (>50% recurrence at 5 years).
Surgical Reimbursement Gap
| Country | Male Procedure | Female Procedure | Disparity |
|---|---|---|---|
| US (RVU) | Urologic procedures | Gynecologic procedures | 31-34% higher male RVU, 20-year trend |
| Germany (G-DRG) | Hernia repair: ~€1,360 | Complex endo: financial loss | DRG diluted by simple cases |
| France (CCAM) | Hernia: €287.56 in 45-60 min | Endo adhesiolysis: €238 in 90-180 min | ~50% €/hour |
| UK (NHS) | Hernia: £1,300-1,600 | Complex endo: same cost, 2× theatre time | Hospital clears 2 hernia patients vs 1 |
The 17:1 ROI
If reimbursement were raised from ~€3,000 to ~€6,000 for expert excision, the additional €3,000 upfront prevents ~€53,000 in societal costs over a decade (avoided re-operations, reduced productivity loss, maintained employment). Net savings: €50,000 per patient.
Note: This is a modeled scenario simulation, not a verified outcome study. The 17:1 figure illustrates the economic logic of the valuation correction. The gap between hospital cost (who pays the uplift) and employer/tax base (who reaps the savings) is a siloed budgeting problem, not a cost-effectiveness problem.
For Decision-Makers
The coding systems you maintain are not neutral - they are price signals. CPT 58662 tells surgeons all endometriosis is the same. Complexity-stratified codes tell them quality matters. Action: Open a coding review on endometriosis, PCOS, and FSD within the next tariff cycle.
Subscription reimbursement ("Netflix model") eliminates the prevalence penalty and provides budget certainty. You already use this for hepatitis C. Action: Model one subscription or outcomes-based pilot for a women's-health asset.
France has ALD 31 (100% endometriosis coverage). Denmark is investing DKK 160M in infrastructure. Companies generating sex-disaggregated evidence now will navigate emerging requirements. Action: Build launch plans around biomarker, coding, and payer-evidence milestones.
Request a Market Access Readiness Brief
What evidence is missing, which reimbursement barrier matters most, and where to pilot first.
Contact FemTechnology →Sources & Evidence Base
All statistics in this analysis are sourced from peer-reviewed literature, government statistical offices, or published claims datasets. Key references:
- WEF/McKinsey Health Institute 2024 - $1T+ GDP opportunity from closing the gap
- Faubion SS et al., Mayo Clin Proc 2023 - DOI: 10.1016/j.mayocp.2023.02.025
- Parker ED et al., Diabetes Care 2024 - DOI: 10.2337/dci22-0078
- DPP Trial, NEJM 2002 - Lifestyle intervention reduces T2D by 58%. DOI: 10.1056/NEJMoa012512